Aborted melanoma trial ends pharma alliance
Synta and GlaxoSmithKline will end their agreement to develop and market elesclomol for the treatment of metastatic melanoma after lackluster results from the SYMMETRY trial.
Synta and GlaxoSmithKline will end their agreement to develop and market elesclomol for the treatment of metastatic melanoma after lackluster results from the SYMMETRY trial.
The late-stage trial evaluated elesclomol plus paclitaxel vs paclitaxel alone in patients with metastatic melanoma. The study was suspended because of a higher mortality rate among patients in the elesclomol treatment arm along with other safety concerns.
The deal between the two companies is expected to be terminated no later than September 10, 2009, after which worldwide rights to elesclomol will revert to Synta.
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
